Logo

SNYR

Synergy CHC Corp.

SNYR

Synergy CHC Corp. • NASDAQ
$2.14 ▼ -1.83% (-0.04)
Market Cap $19.18 M
52w High $5.99
52w Low $1.30
Dividend Yield 0%
P/E 7.64
Volume 8.47K
Outstanding Shares 8.96M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $8.01M ▼ $4.367M ▼ $125.327K ▼ 1.565% ▼ $0.01 ▼ $1.312M ▼
Q2-2025 $8.135M ▼ $4.615M ▲ $1.473M ▲ 18.11% ▲ $0.17 ▲ $3.804M ▲
Q1-2025 $8.171M ▼ $4.216M ▼ $876.264K ▲ 10.725% ▲ $0.1 ▲ $1.994M ▲
Q4-2024 $10.271M ▲ $5.143M ▲ $105.667K ▼ 1.029% ▼ $0.014 ▼ $1.673M ▲
Q3-2024 $7.126M $3.74M $783.593K 10.996% $0.1 $1.329M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.106M ▼ $20.691M ▲ $28.943M ▼ $-8.252M ▲
Q2-2025 $1.459M ▲ $19.726M ▲ $32.106M ▲ $-12.379M ▲
Q1-2025 $177.882K ▼ $15.656M ▼ $31.295M ▼ $-15.639M ▲
Q4-2024 $687.92K ▲ $16.343M ▲ $32.974M ▼ $-16.631M ▲
Q3-2024 $259.375K $12.17M $37.339M $-25.169M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $125.327K ▼ $-2.309M ▼ $0 $1.883M ▲ $-452.072K ▼ $-2.309M ▼
Q2-2025 $1.473M ▲ $-76.95K ▲ $0 $1.318M ▲ $1.281M ▲ $-76.95K ▲
Q1-2025 $876.264K ▲ $-822.781K ▲ $0 $314.678K ▼ $-510.038K ▼ $-822.781K ▲
Q4-2024 $105.667K ▼ $-3.426M ▼ $0 $3.908M ▲ $428.545K ▲ $-3.426M ▼
Q3-2024 $783.593K $-237.474K $0 $488.581K $172.082K $-237.474K

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
License
License
 $0 ▲$0 ▲$0 ▲$0 ▲
Retail
Retail
 $20.00M ▲$0 ▼$0 ▲$10.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Synergy’s income statement shows a very small business with fairly flat sales over the last few years and only modest recent improvement. Profitability has swung from roughly breakeven, to loss, and then back toward slight profit, so the earnings profile is still fragile and inconsistent. The move into positive operating results in recent periods is encouraging, but given the tiny scale, even small setbacks in demand or pricing could push results back into the red. Per‑share figures have been heavily distorted by reverse splits, so they overstate any apparent improvement in underlying performance.

Balance Sheet

Balance Sheet The balance sheet is a clear weak spot. Assets are limited while borrowings are relatively heavy for a company of this size, and shareholders’ equity is now negative, which means obligations exceed the book value of what the company owns. This structure leaves the company financially thinly cushioned and more exposed to lenders’ expectations and market volatility. Any future growth likely depends on careful management of debt and access to external capital, as there does not appear to be much balance‑sheet slack.

Cash Flow

Cash Flow Cash flow from the core business has hovered around breakeven, with an earlier period of cash burn followed by more stable but still modest cash generation. The company does not appear to invest heavily in physical assets, which keeps capital spending low but also suggests growth depends more on marketing and brand deals than on hard infrastructure. The overall picture is of a business that is not yet throwing off reliable, surplus cash and has limited internal funding capacity for major new initiatives or acquisitions.

Competitive Edge

Competitive Edge Synergy competes in crowded, trend‑driven consumer health and wellness niches, where brand strength and marketing execution matter more than traditional medical moats. Its edge comes from a portfolio of recognizable brands like FOCUSfactor and Flat Tummy, broad retail and online distribution, and a fast‑moving digital marketing engine that leans heavily on data and social media. This model can scale quickly when a brand resonates, but it also leaves the company exposed to shifting consumer tastes, intense competition from copycats, and scrutiny over product claims. The lawsuit challenging FOCUSfactor’s efficacy and the highly promotional nature of some products underline ongoing reputational and regulatory risk.

Innovation and R&D

Innovation and R&D Innovation at Synergy is less about heavy scientific research and more about proprietary formulations paired with sophisticated, analytics‑driven marketing. The company has built value around clinically framed products like FOCUSfactor, niche offerings such as Hand MD and Neuragen, and influencer‑driven brands like Flat Tummy, then amplified them through its in‑house digital growth platform. A notable newer push is into functional beverages under the FOCUSfactor name, which taps into a fast‑growing category but will attract many rivals. Overall, the innovation engine is agile and brand‑centric, but its success depends on continuously finding, acquiring, and refreshing concepts that keep consumer attention while staying on the right side of regulators and public perception.

Summary

Overall, Synergy CHC is a very small, brand‑driven healthcare and wellness company with a marketing‑heavy growth model. The business has recently edged back toward profitability and stabilized cash usage, but revenues remain small and relatively flat, with a balance sheet that is thin and heavily reliant on debt. Its main strengths lie in consumer brands, broad retail and online access, and a nimble approach to digital marketing and acquisitions. Key risks include weak equity backing, legal and reputational exposure around product claims, intense competition in supplements and wellness drinks, and limited internally generated cash to fund growth. Future performance will hinge on the company’s ability to scale newer initiatives like functional beverages, successfully integrate additional brands, and gradually strengthen its financial foundation.

NEWS

November 5, 2025 · 8:00 AM UTC

Synergy CHC Corp Expands FOCUSfactor® Functional Beverage Distribution Across Arkansas Through Partnership with C&M Sales

Read more

September 17, 2025 · 9:06 AM UTC

Synergy CHC Corp. (NASDAQ: SNYR) Partners with AlaBev to Launch FOCUSfactor® Beverages in 5,000+ Retail Outlets Across Alabama

Read more